| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| trastuzumab metastatic breast cancer | 1.3 | 0.8 | 2357 | 54 | 36 |
| trastuzumab | 1.81 | 0.2 | 9903 | 16 | 11 |
| metastatic | 0.43 | 0.3 | 9557 | 47 | 10 |
| breast | 1.48 | 1 | 6737 | 71 | 6 |
| cancer | 1.34 | 0.7 | 6071 | 53 | 6 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| trastuzumab metastatic breast cancer | 0.67 | 0.6 | 4506 | 1 |
| trastuzumab breast cancer treatment | 0.15 | 0.2 | 4379 | 49 |
| resistance to trastuzumab in breast cancer | 1.19 | 1 | 2800 | 31 |
| trastuzumab side effects breast cancer | 1.53 | 0.3 | 6644 | 96 |
| adjuvant trastuzumab breast cancer | 1.08 | 0.9 | 3050 | 93 |
| trastuzumab her2-positive breast cancer | 0.87 | 0.7 | 5005 | 49 |
| pertuzumab in metastatic breast cancer ppt | 1.44 | 0.9 | 3697 | 27 |
| trastuzumab deruxtecan breast cancer | 0.27 | 0.8 | 4954 | 16 |
| trastuzumab for gastric cancer | 1.44 | 0.2 | 4802 | 66 |
| trastuzumab is a chemo drug | 0.44 | 0.8 | 9447 | 25 |
| is trastuzumab a chemotherapy drug | 1.83 | 1 | 9232 | 35 |
| trastuzumab emtansine lung cancer | 1.59 | 0.1 | 8584 | 13 |
| is trastuzumab considered chemotherapy | 1.99 | 0.2 | 1467 | 63 |
| trastuzumab + pertuzumab + chemotherapy | 1.5 | 0.2 | 9830 | 97 |
| trastuzumab gastric cancer fda approval | 1.23 | 1 | 3949 | 1 |
| trastuzumab chemotherapy or immunotherapy | 1.48 | 0.6 | 3187 | 64 |
| sacituzumab govitecan breast cancer | 1.08 | 0.2 | 4137 | 93 |
| why is trastuzumab given after chemotherapy | 0.12 | 0.3 | 1158 | 54 |
